Sun Pharma Share Price in Focus; Organon Shareholders Approve Proposed Acquisition

Sun Pharmaceutical Industries Ltd. announced that the shareholders of Organon & Co. have approved the proposals related to the company's previously announced acquisition. The approval represents a significant step towards completing the transaction under which Organon will become an indirect wholly-owned subsidiary of Sun Pharma.  

Organon Shareholders Approve Acquisition Proposal 

According to the company, Organon's shareholders have approved the proposals connected with the merger transaction. Following completion, Organon is expected to become a wholly-owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly-owned subsidiary of Sun Pharma.  

Transaction Moves Closer to Completion 

Sun Pharma stated that the shareholder approval marks an important milestone in the acquisition process. However, the transaction has not yet been completed and remains subject to the fulfilment of the remaining customary closing conditions.  

Regulatory Approvals Still Pending 

The company said the proposed acquisition continues to require applicable regulatory approvals and satisfaction of other customary closing conditions before the transaction can be completed. Sun Pharma also referred investors to its April 27, 2026 announcement for additional details regarding the acquisition.  

Read More: Fintech Collaborations Help Smaller Banks Win More Credit Card Customers in FY26! 

Share Price Performance 

As of July 24, 2026, at 1:43 PM, Sun Pharmaceutical Industries share price was trading at ₹1,940.00 per share, reflecting a decline of 0.72% from the previous trading session. 

Conclusion 

Organon shareholders have approved the proposed acquisition by Sun Pharma. The transaction remains subject to regulatory approvals and other customary closing conditions before it is completed.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Take action on today’s market news - Complete your Demat Account Opening now.